ZhuZhou Central Hospital
14
9
9
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 14 trials
29%
4 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
A Prospective Multicenter Observational Real-world Study of Retained Products of Conception
Role: collaborator
Intensive Cholesterol-Lowering Within 24 Hours of PCI Perioperative Period
Role: collaborator
Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction
Role: collaborator
Clinical Study on the Treatment of Stable Bronchiectasis With Bailing Capsules Combined With Guben Kechuan Granules
Role: collaborator
ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC
Role: collaborator
Effect of Premedication With Pronase on Mucosal Cleanliness During EGD
Role: collaborator
Validation of an AI-Assisted Mediastinal EUS System for Training Improvement: a Prospective, Multi-Center, Randomized Trial
Role: collaborator
Validation of an AI-Assisted Pancreatic EUS System for Training Improvement: a Prospective, Multi-Center, Randomized Trial
Role: collaborator
Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
Role: collaborator
Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)
Role: collaborator
TEER for Severe DMR of Low to Intermediate Surgery Risk
Role: collaborator
SNP-based Prediction of Recurrence Risk in Kidney Stone Patients
Role: collaborator
Cerebral Lesion and Neurocognitive Status Changes After TAVR
Role: collaborator
Population Pharmacokinetics of Tacrolimus in Nephrotic Syndrome
Role: collaborator
All 14 trials loaded